Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells

Journal of Neurochemistry

Volumn 137, Issue 5, 2016, Pages 782-794

  Dobson, Lucianne ^a   Träger, Ulrike ^a,b   Farmer, Ruth ^c   Hayardeny, Liat ^d   Loupe, Pippa ^d   Hayden, Michael R ^d   Tabrizi, Sarah J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d TEVA PHARMACEUTICALS   (Israel)

Author keywords

cytokines; Huntington's disease; inflammation; laquinimod; neurodegenerative disease; NF B

Indexed keywords

HUNTINGTIN; I KAPPA B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 8; LAQUINIMOD; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; CELL STIMULATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG CYTOTOXICITY; EX VIVO STUDY; FEMALE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOMODULATION; IMMUNOSTIMULATION; MALE; MONOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; BONE MARROW CELL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; HUNTINGTON DISEASE; METABOLISM; MIDDLE AGED;

ADULT; AGED; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MYELOID CELLS; QUINOLONES;

EID: 84959445561     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13553     Document Type: Article

References (44)

1. Björkqvist M., Wild E. J., Thiele J., et al,. (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 205, 1869-1877.
2. Bouchard J., Truong J., Bouchard K., Dunkelberger D., Desrayaud S., Moussaoui S., Tabrizi S. J., Stella N., and, Muchowski P. J., (2012) Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J. Neurosci. Off. J. Soc. Neurosci. 32, 18259-18268.
3. Brück W., and, Wegner C., (2011) Insight into the mechanism of laquinimod action. J. Neurol. Sci. 306, 173-179.
4. Brück W., Pförtner R., Pham T., et al,. (2012) Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. (Berl.) 124, 411-424.
5. Brunmark C., Runström A., Ohlsson L., Sparre B., Brodin T., Aström M., and, Hedlund G., (2002) The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130, 163-172.
6. Chakrabarty P., Li A., Ceballos-Diaz C., et al,. (2015) IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85, 519-533.
7. Chen M., Ona V. O., Li M., et al,. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6, 797-801.
8. Comi G., Jeffery D., Kappos L., Montalban X., Boyko A., Rocca M. A., and, Filippi M., (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 366, 1000-1009.
9. Cunningham C., Campion S., Teeling J., Felton L., and, Perry V. H., (2007) The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C). Brain Behav. Immun. 21, 490-502.
10. Dalrymple A., Wild E. J., Joubert R., et al,. (2007) Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 6, 2833-2840.
11. Ellrichmann G., Petrasch-Parwez E., Lee D.-H., Reick C., Arning L., Saft C., Gold R., and, Linker R. A., (2011) Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS ONE 6, e16172.
12. Ellrichmann G., Reick C., Saft C., and, Linker R. A., (2013) The role of the immune system in Huntington's disease. Clin. Dev. Immunol. 2013, 541259.
13. Filippi M., Rocca M. A., Pagani E., De Stefano N., Jeffery D., Kappos L., Montalban X., Boyko A. N., and, Comi G,., ALLEGRO Study Group (2014) Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J. Neurol. Neurosurg. Psychiatry 85, 851-858.
14. Guillot-Sestier M.-V., Doty K. R., Gate D., Rodriguez J., Leung B. P., Rezai-Zadeh K., and, Town T., (2015) Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85, 534-548.
15. Gurevich M., Gritzman T., Orbach R., Tuller T., Feldman A., and, Achiron A., (2010) Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J. Neuroimmunol. 221, 87-94.
16. Hayden M. S., and, Ghosh S., (2012) NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 26, 203-234.
17. Hsiao H.-Y., Chen Y.-C., Chen H.-M., Tu P.-H., and, Chern Y., (2013) A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease. Hum. Mol. Genet., 22, 1826-1842.
18. Huntington Study Group DOMINO Investigators (2010) A futility study of minocycline in Huntington's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 25, 2219-2224.
19. Khoshnan A., Ko J., Watkin E. E., Paige L. A., Reinhart P. H., and, Patterson P. H., (2004) Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci. Off. J. Soc. Neurosci. 24, 7999-8008.
20. Kwan W., Magnusson A., Chou A., et al,. (2012a) Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J. Neurosci. Off. J. Soc. Neurosci. 32, 133-142.
21. Kwan W., Träger U., Davalos D., et al,. (2012b) Mutant huntingtin impairs immune cell migration in Huntington disease. J. Clin. Invest. 122, 4737-4747.
22. Martinez F. O., and, Gordon S., (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime Rep. 6, 13.
23. Mishra M. K., Wang J., Keough M. B., Fan Y., Silva C., Sloka S., Hayardeny L., Brück W., and, Yong V. W., (2014) Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Ann. Clin. Transl. Neurol. 1, 409-422.
24. Palin K., Cunningham C., Forse P., Perry V. H., and, Platt N., (2008) Systemic inflammation switches the inflammatory cytokine profile in CNS Wallerian degeneration. Neurobiol. Dis. 30, 19-29.
25. Pavese N., Gerhard A., Tai Y. F., Ho A. K., Turkheimer F., Barker R. A., Brooks D. J., and, Piccini P., (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66, 1638-1643.
26. Perry V. H., (2007) Stress primes microglia to the presence of systemic inflammation: implications for environmental influences on the brain. Brain Behav. Immun. 21, 45-46.
27. Perry V. H., Cunningham C., and, Holmes C., (2007) Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 7, 161-167.
28. Politis M., Pavese N., Tai Y. F., Kiferle L., Mason S. L., Brooks D. J., Tabrizi S. J., Barker R. A., and, Piccini P., (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum. Brain Mapp. 32, 258-270.
29. Poltorak A., He X., Smirnova I., et al,. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088.
30. Preiningerova J., (2009) Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin. Investig. Drugs 18, 985-989.
31. Qureshi S. T., Larivière L., Leveque G., Clermont S., Moore K. J., Gros P., and, Malo D., (1999) Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189, 615-625.
32. Ross C. A., and, Tabrizi S. J., (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98.
33. Sapp E., Kegel K. B., Aronin N., Hashikawa T., Uchiyama Y., Tohyama K., Bhide P. G., Vonsattel J. P., and, DiFiglia M., (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161-172.
34. Schulze-Topphoff U., Shetty A., Varrin-Doyer M., Molnarfi N., Sagan S. A., Sobel R. A., Nelson P. A., and, Zamvil S. S., (2012) Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS ONE 7, e33797.
35. Sennbro C. J., Olin M., Edman K., Hansson G., Gunnarsson P. O., and, Svensson L. D., (2006) Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling. Rapid Commun. Mass Spectrom. RCM 20, 3313-3318.
36. Tai Y., Pavese N., Gerhard A., Tabrizi S. J., Barker R., Brooks D., and, Piccini P., (2007) Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 130, 1759-1766.
37. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
38. Thomas M., Ashizawa T., and, Jankovic J., (2004) Minocycline in Huntington's disease: a pilot study. Mov. Disord. Off. J. Mov. Disord. Soc. 19, 692-695.
39. Träger U., Andre R., Lahiri N., et al,. (2014) HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain, 137, 819-833.
40. Vollmer T. L., Sorensen P. S., Selmaj K., Zipp F., Havrdova E., Cohen J. A., Sasson N., Gilgun-Sherki Y., and, Arnold D. L., BRAVO Study Group (2014) A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J. Neurol. 261, 773-783.
41. Wild E., Magnusson A., Lahiri N., Krus U., Orth M., Tabrizi S. J., and, Björkqvist M., (2011) Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr. 3, RRN1231.
42. Yang J.-S., Xu L.-Y., Xiao B.-G., Hedlund G., and, Link H., (2004) Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 156, 3-9.
43. Zou L.-P., Abbas N., Volkmann I., Nennesmo I., Levi M., Wahren B., Winblad B., Hedlund G., and, Zhu J., (2002) Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 42, 731-739.
44. Zwilling D., Huang S.-Y., Sathyasaikumar K. V., et al,. (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863-874.